NCT03061318 (CT-DS) is a clinical trial in Indeterminate Thyroid Cytology, sponsored by Hernán González.

Who is sponsoring NCT03061318?

NCT03061318 is sponsored by Hernán González.

What condition does NCT03061318 study?

NCT03061318 studies Indeterminate Thyroid Cytology.

Is NCT03061318 still recruiting?

NCT03061318 is currently completed. Last updated 31 October 2017.

Last reviewed 2017-10-31 · How we verify

NCT03061318: CT-DS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Validation of a Multi-Genetic Test for the Diagnosis of Indeterminate Thyroid Nodules

Completed Last updated 31 October 2017

What this trial tests

trial in Indeterminate Thyroid Cytology in 3,100 participants. Completed in 30 August 2017.

Timeline

8 August 2015

Primary endpoint
30 August 2017

30 August 2017

Quick facts

Lead sponsor	Hernán González
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3,100
Start date	8 August 2015
Primary completion	30 August 2017
Estimated completion	30 August 2017
Sites	9 locations across Chile

Conditions studied

Indeterminate Thyroid Cytology — all drugs for Indeterminate Thyroid Cytology →

Sponsor

Hernán González

Who can join

18 and older, any sex, with Indeterminate Thyroid Cytology. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A clinical trial is proposed, to clinically validate the diagnostic performance of a new genetic test developed in Chile. It will determine the nature of thyroid nodules that have been informed as indeterminate by cytology through a fine needle aspiration (FNA). The Genetic Classifier for Indeterminate Thyroid Nodules is a quantitative gene expression test, that combines the results for a panel of 10 biomarkers (CXCR3, CCR3, CXCl10, CK19, TIMP1, CLDN1, CAR, XB130, HO-1 and CCR7), to generate a single number score. It is indicated on patients with a thyroid nodule informed by cytology as indeterminate (Bethesda III and IV, according to The Bethesda System for Reporting Thyroid Cytopathology). This test would be used by taking a sample with a fine needle aspiration (FNA) and thus, being able to predict, with high accuracy, benign nodules that do not require surgery.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Thyroid Genetic Classifier Correctly Predicts Benign Nodules with Indeterminate Cytology: Two Independent, Multicenter, Prospective Validation Trials.
Zafereo M, McIver B, Vargas-Salas S, Domínguez JM, et al · · 2020 · cited 25× · PMID 31910118 · DOI 10.1089/thy.2019.0490

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03061318 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hernán González
Last refreshed: 31 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03061318.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing